Comparison of the effects of mGluR1 and mGluR5 antagonists on the expression of behavioral sensitization to the locomotor effect of morphine and the morphine withdrawal jumping in mice

The aim of the present study was to compare the influence of group I metabotropic glutamate receptor (mGluR) antagonists (mGluR1 and mGluR5) on the expression of sensitization to the locomotor effect of morphine. We also tested how these compounds affect the morphine withdrawal jumps in mice. In our study, the mGluR1 antagonist EMQMCM [3-ethyl-2-methyl-quinolin-6-yl-(4-methoxy-cyclohexyl)-methanone methanesulfonate) and the mGluR5 antagonist MTEP ([(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine) were used. Sensitization was induced by five intraperitoneal (i.p.) injections of morphine at the dose of 10 mg/kg, every 3 days. Morphine dependence was induced by subcutaneous (s.c.) implantation of pellets containing 37.5 mg of morphine base for three days. Our data indicate that pretreatment with EMQMCM (5, 10, 20 mg/kg) and MTEP (5, 10 mg/kg) on the challenge day, inhibited the expression of sensitization to the locomotor effect of morphine in mice. Antagonists of both subtypes of the group I mGlurs given alone, did not modify the acute locomotor effect of morphine. On the other hand, EMQMCM did not attenuate the morphine withdrawal jumps precipitated by naloxone (4 mg/kg). The results suggest that both subtypes of the group I mGluRs (mGluR1 and mGluR5) take part in the expression of morphine sensitization processes but mGluRI is not involved in the expression of morphine withdrawal jumps in mice. These findings may have implications for the treatment of opiate addiction in future. (c) 2006 Elsevier B.V. All rights reserved.